{"id":"ketoprofen-rp19583","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Gastrointestinal upset (dyspepsia, nausea)"},{"rate":"5-15","effect":"Abdominal pain"},{"rate":"5-10","effect":"Headache"},{"rate":"3-8","effect":"Dizziness"},{"rate":"1-2","effect":"Gastrointestinal bleeding (serious)"},{"rate":"1-2","effect":"Cardiovascular events (serious)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a nonsteroidal anti-inflammatory drug (NSAID), ketoprofen blocks both COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammatory responses and pain signaling. By reducing prostaglandin levels, the drug provides analgesic, anti-inflammatory, and antipyretic effects. RP19583 likely represents a specific formulation or modified-release variant of ketoprofen designed to optimize therapeutic delivery.","oneSentence":"Ketoprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:51.125Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute and chronic pain"},{"name":"Rheumatoid arthritis"},{"name":"Osteoarthritis"},{"name":"Ankylosing spondylitis"}]},"trialDetails":[{"nctId":"NCT06731647","phase":"PHASE2","title":"Non-steroidal Anti-inflammatory Drugs in Pleurodesis","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2025-02-01","conditions":"Non-steroidal Anti-inflammatory Drugs, Pleurodesis, Pneumothorax","enrollment":358},{"nctId":"NCT00929877","phase":"PHASE3","title":"KRYSTAL- KetopRofen lYsinate Sore ThroAt Lozenges","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-06","conditions":"Pain","enrollment":801}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"KETOPROFEN(RP19583)","genericName":"KETOPROFEN(RP19583)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ketoprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Used for Acute and chronic pain, Rheumatoid arthritis, Osteoarthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}